JP2004517852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517852A5 JP2004517852A5 JP2002552939A JP2002552939A JP2004517852A5 JP 2004517852 A5 JP2004517852 A5 JP 2004517852A5 JP 2002552939 A JP2002552939 A JP 2002552939A JP 2002552939 A JP2002552939 A JP 2002552939A JP 2004517852 A5 JP2004517852 A5 JP 2004517852A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- inden
- cyclopenta
- aza
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- -1 3-oxetanyl Chemical group 0.000 claims 13
- 206010012601 diabetes mellitus Diseases 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229940086609 Lipase inhibitor Drugs 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 206010012655 Diabetic complications Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000016222 Pancreatic disease Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010064 diabetes insipidus Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 3
- 229960001243 orlistat Drugs 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 125000006224 2-tetrahydrofuranylmethyl group Chemical group [H]C([H])(*)C1([H])OC([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000027626 Neurocognitive disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 201000000484 premenstrual tension Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- DSDJWMWJRKCKCE-VIFPVBQESA-N (2s)-1-(5-fluoro-6-methoxy-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound COC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1F DSDJWMWJRKCKCE-VIFPVBQESA-N 0.000 claims 1
- FWXXHTBFBYUWTJ-NSHDSACASA-N (2s)-1-(6-cyclopropyloxy-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound C1=C2C(C[C@@H](N)C)=C3CCCN3C2=CC=C1OC1CC1 FWXXHTBFBYUWTJ-NSHDSACASA-N 0.000 claims 1
- IMDCAWVCNYESQC-JTQLQIEISA-N (2s)-1-(6-cyclopropyloxy-5-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound FC1=C2C(C[C@@H](N)C)=C3CCCN3C2=CC=C1OC1CC1 IMDCAWVCNYESQC-JTQLQIEISA-N 0.000 claims 1
- QCPKALQXQKTTQB-NSHDSACASA-N (2s)-1-(6-ethoxy-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound CCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 QCPKALQXQKTTQB-NSHDSACASA-N 0.000 claims 1
- SLLLMJVQCBMSLS-JTQLQIEISA-N (2s)-1-(6-ethoxy-5-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound CCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1F SLLLMJVQCBMSLS-JTQLQIEISA-N 0.000 claims 1
- ZHZJODQADCZMHK-JTQLQIEISA-N (2s)-1-(6-ethoxy-7-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound C1=C(F)C(OCC)=CC2=C1N1CCCC1=C2C[C@H](C)N ZHZJODQADCZMHK-JTQLQIEISA-N 0.000 claims 1
- XDEGBBONBCMCHL-NSHDSACASA-N (2s)-1-[5-fluoro-6-(2-methoxyethoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1F XDEGBBONBCMCHL-NSHDSACASA-N 0.000 claims 1
- JYZQZNBKKFSHLV-LBPRGKRZSA-N (2s)-1-[5-fluoro-6-(3-methoxypropoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1F JYZQZNBKKFSHLV-LBPRGKRZSA-N 0.000 claims 1
- SWVILPKDPUXYKT-ZDUSSCGKSA-N (2s)-1-[6-(2-ethoxyethoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound CCOCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 SWVILPKDPUXYKT-ZDUSSCGKSA-N 0.000 claims 1
- YZMZCUJIBWXFLB-LBPRGKRZSA-N (2s)-1-[6-(2-methoxyethoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 YZMZCUJIBWXFLB-LBPRGKRZSA-N 0.000 claims 1
- LWJJTMYOGQVLNI-AWEZNQCLSA-N (2s)-1-[6-(3-ethoxypropoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound CCOCCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 LWJJTMYOGQVLNI-AWEZNQCLSA-N 0.000 claims 1
- OLMCBWTZMZYKJY-ZDUSSCGKSA-N (2s)-1-[6-(3-methoxypropoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 OLMCBWTZMZYKJY-ZDUSSCGKSA-N 0.000 claims 1
- DETWXRAGLCWMEP-AWEZNQCLSA-N (2s)-1-[6-(4-methoxybutoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 DETWXRAGLCWMEP-AWEZNQCLSA-N 0.000 claims 1
- FOUAYMJKLOFDEH-AWEZNQCLSA-N (2s)-1-[6-[2-(2-methoxyethoxy)ethoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCOCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 FOUAYMJKLOFDEH-AWEZNQCLSA-N 0.000 claims 1
- MYBNYWOIGBQJRH-HNNXBMFYSA-N (2s)-1-[6-[3-(2-methoxyethoxy)propoxy]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound COCCOCCCOC1=CC=C2N(CCC3)C3=C(C[C@H](C)N)C2=C1 MYBNYWOIGBQJRH-HNNXBMFYSA-N 0.000 claims 1
- PDIUQBQZLVEAMP-NSHDSACASA-N (2s)-1-[7-fluoro-6-(2-methoxyethoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound C1=C(F)C(OCCOC)=CC2=C1N1CCCC1=C2C[C@H](C)N PDIUQBQZLVEAMP-NSHDSACASA-N 0.000 claims 1
- WVWSXKFURMFREJ-LBPRGKRZSA-N (2s)-1-[7-fluoro-6-(3-methoxypropoxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl]propan-2-amine Chemical compound C1=C(F)C(OCCCOC)=CC2=C1N1CCCC1=C2C[C@H](C)N WVWSXKFURMFREJ-LBPRGKRZSA-N 0.000 claims 1
- PXMNBTNIDJTYFM-NSHDSACASA-N 2-[[4-[(2s)-2-aminopropyl]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl]oxy]ethanol Chemical compound C12=CC=C(OCCO)C=C2C(C[C@@H](N)C)=C2N1CCC2 PXMNBTNIDJTYFM-NSHDSACASA-N 0.000 claims 1
- QHRMILCSVOCHAN-JTQLQIEISA-N 2-[[4-[(2s)-2-aminopropyl]-5-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl]oxy]ethanol Chemical compound C12=CC=C(OCCO)C(F)=C2C(C[C@@H](N)C)=C2N1CCC2 QHRMILCSVOCHAN-JTQLQIEISA-N 0.000 claims 1
- CZTBECHUFDKWPR-JTQLQIEISA-N 2-[[4-[(2s)-2-aminopropyl]-7-fluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl]oxy]ethanol Chemical compound C12=CC(F)=C(OCCO)C=C2C(C[C@@H](N)C)=C2N1CCC2 CZTBECHUFDKWPR-JTQLQIEISA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0031724A GB0031724D0 (en) | 2000-12-27 | 2000-12-27 | Indole derivatives |
| GB0119820A GB0119820D0 (en) | 2001-08-14 | 2001-08-14 | Indole derivatives |
| PCT/EP2001/014781 WO2002051844A1 (en) | 2000-12-27 | 2001-12-14 | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517852A JP2004517852A (ja) | 2004-06-17 |
| JP2004517852A5 true JP2004517852A5 (OSRAM) | 2005-05-26 |
| JP4094950B2 JP4094950B2 (ja) | 2008-06-04 |
Family
ID=26245498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002552939A Expired - Fee Related JP4094950B2 (ja) | 2000-12-27 | 2001-12-14 | インドール誘導体および５−ｈｔ２ｂおよび５−ｈｔ２ｃ受容体リガンドとしてのそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6610685B2 (OSRAM) |
| EP (1) | EP1347979B1 (OSRAM) |
| JP (1) | JP4094950B2 (OSRAM) |
| KR (1) | KR100539143B1 (OSRAM) |
| CN (1) | CN1250549C (OSRAM) |
| AR (1) | AR035722A1 (OSRAM) |
| AT (1) | ATE369368T1 (OSRAM) |
| AU (1) | AU2002228007B2 (OSRAM) |
| BR (1) | BR0116605A (OSRAM) |
| CA (1) | CA2432085C (OSRAM) |
| DE (1) | DE60129841T2 (OSRAM) |
| ES (1) | ES2291374T3 (OSRAM) |
| MX (1) | MXPA03005915A (OSRAM) |
| PE (1) | PE20020911A1 (OSRAM) |
| UY (1) | UY27097A1 (OSRAM) |
| WO (1) | WO2002051844A1 (OSRAM) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003243089B2 (en) | 2002-06-19 | 2010-01-07 | Biovitrum Ab (Publ) | Novel compounds, their use and preparation |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| US7547693B2 (en) | 2003-09-22 | 2009-06-16 | Banyu Pharmaceutical Co. Ltd. | Piperidine derivative |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| EP1792629A4 (en) | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| JP2008518917A (ja) | 2004-11-01 | 2008-06-05 | ワイス | Ｃｎｓ薬剤としての置換インドリジンおよび誘導体 |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDOLVERBINDUNG |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
| EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| AU2006304836A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
| NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
| CN101321761A (zh) | 2005-12-09 | 2008-12-10 | 霍夫曼-拉罗奇有限公司 | 用于治疗肥胖病的三环酰胺衍生物 |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
| BRPI0806774A2 (pt) | 2007-01-16 | 2011-09-13 | Ipintl Llc | composição para tratamento de sìndrome metabólica |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
| CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
| AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2510949A4 (en) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MY159058A (en) | 2011-02-25 | 2016-12-15 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent |
| CN108676076A (zh) | 2011-03-01 | 2018-10-19 | 辛纳吉制药公司 | 制备鸟苷酸环化酶c激动剂的方法 |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| HK1220696A1 (zh) | 2013-03-15 | 2017-05-12 | Bausch Health Ireland Limited | 鸟苷酸环化酶激动剂及其用途 |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| TWI767945B (zh) | 2016-10-14 | 2022-06-21 | 義大利商Ｔｅｓ製藥（股份）責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| CN113302189B (zh) | 2018-11-20 | 2025-09-05 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CN116249697A (zh) | 2020-08-18 | 2023-06-09 | 默沙东有限责任公司 | 二环庚烷吡咯烷食欲素受体激动剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| TW270114B (OSRAM) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| JP3560986B2 (ja) | 1997-01-13 | 2004-09-02 | 山之内製薬株式会社 | ５―ｈｔ２ｃ受容体作用薬及びアミノアルキルインダゾール誘導体 |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| AU759388B2 (en) | 1998-08-14 | 2003-04-10 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
| IL143323A0 (en) * | 1998-12-17 | 2002-04-21 | American Home Prod | 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
-
2001
- 2001-12-14 AT AT01989597T patent/ATE369368T1/de not_active IP Right Cessation
- 2001-12-14 CN CNB018213510A patent/CN1250549C/zh not_active Expired - Fee Related
- 2001-12-14 JP JP2002552939A patent/JP4094950B2/ja not_active Expired - Fee Related
- 2001-12-14 AU AU2002228007A patent/AU2002228007B2/en not_active Ceased
- 2001-12-14 MX MXPA03005915A patent/MXPA03005915A/es active IP Right Grant
- 2001-12-14 EP EP01989597A patent/EP1347979B1/en not_active Expired - Lifetime
- 2001-12-14 WO PCT/EP2001/014781 patent/WO2002051844A1/en not_active Ceased
- 2001-12-14 BR BR0116605-0A patent/BR0116605A/pt not_active IP Right Cessation
- 2001-12-14 DE DE60129841T patent/DE60129841T2/de not_active Expired - Lifetime
- 2001-12-14 US US10/017,978 patent/US6610685B2/en not_active Expired - Fee Related
- 2001-12-14 ES ES01989597T patent/ES2291374T3/es not_active Expired - Lifetime
- 2001-12-14 CA CA002432085A patent/CA2432085C/en not_active Expired - Fee Related
- 2001-12-14 KR KR10-2003-7008679A patent/KR100539143B1/ko not_active Expired - Fee Related
- 2001-12-21 PE PE2001001298A patent/PE20020911A1/es not_active Application Discontinuation
- 2001-12-21 AR ARP010106000A patent/AR035722A1/es not_active Application Discontinuation
- 2001-12-26 UY UY27097A patent/UY27097A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517852A5 (OSRAM) | ||
| JP2005521671A5 (OSRAM) | ||
| AU2018282336B2 (en) | Trk-inhibiting compound | |
| AU2014337298B2 (en) | Hepatitis B viral assembly effectors | |
| CN102639530B (zh) | 作为α7正向变构调节剂的吗啉代噻唑 | |
| JP5952917B2 (ja) | ベンゾチオフェン化合物又はその塩の、二水和物、及びその製造方法 | |
| CN102753551B (zh) | 作为pde10a酶抑制剂的2-芳基咪唑衍生物 | |
| CN1419552A (zh) | 2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂 | |
| JP5654559B2 (ja) | キナゾリンジオン誘導体の治療での使用 | |
| JP2009538867A5 (OSRAM) | ||
| JP2012526735A5 (OSRAM) | ||
| CN101263130A (zh) | 2-苯胺-4-芳基取代的噻唑衍生物 | |
| TW200738233A (en) | Use of substituted 2-imidazole or imidazoline derivatives | |
| JP2007508361A5 (OSRAM) | ||
| JP2011509297A5 (OSRAM) | ||
| CN1706813A (zh) | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 | |
| CN1201461A (zh) | 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物 | |
| JP5564101B2 (ja) | キナゾリンジオン誘導体、その調製およびその様々な治療上の使用 | |
| US10590128B2 (en) | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | |
| CN1545411A (zh) | 环丙基和环丁基埃坡霉素类似物 | |
| JP2019537590A5 (OSRAM) | ||
| JP5822079B2 (ja) | 疼痛治療剤 | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| AU2007258506A1 (en) | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | |
| JP2011116663A (ja) | ベンゾジアゼピン化合物 |